Early thrombogenicity of coronary stents: comparison of bioresorbable polymer sirolimus-eluting and bare metal stents in an aortic rat model.
Stent
animal model
platelet
thrombus
Journal
American journal of cardiovascular disease
ISSN: 2160-200X
Titre abrégé: Am J Cardiovasc Dis
Pays: United States
ID NLM: 101569582
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
04
2020
accepted:
16
05
2020
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
21
7
2020
Statut:
epublish
Résumé
Although 1-month dual antiplatelet therapy (DAPT) in patients treated with bare metal stents (BMS) is well established, the optimal duration of DAPT after implantation of a drug-eluting stent (DES) is still a matter of debate. The safety of shortened DAPT is under investigation due to concern about the risk of stent thrombosis. Data on platelet activation and prothrombotic response in vivo following bioresorbable polymer sirolimus-eluting stent (BP-SES) implantation are scarce. The aim of our study was to compare the early thrombogenicity of BP-SES with that of BMS in an aortic rat model. Overall, 30 rats underwent stent implantation in the abdominal aorta: BMS (Pro-Kinetic Energy; N=15) and BP-SES (Ultimaster Tansei; N=15) were compared in terms of their early thrombogenicity. CD62P exposure at the platelet surface and fibrinogen binding at the integrin receptor were not different between BMS and BP-SES over time. The thrombus coverage of the scaffold (0 vs. 0.1%, P=0.84) was similarly low in both groups at Day 28; thrombotic deposits had totally disappeared at Day 84. The endothelial strut coverage was similarly high at 1 month (90 vs. 95%, P=0.64) and 3 months (87 vs. 97%, P=0.99) following BMS and BP-SES implantation, respectively. This study demonstrates the low early thrombogenicity of a BP-SES implanted in an aortic rat model, which did not differ from a BMS. These data could be helpful to support the safety of a shortened 1-month DAPT duration following BP-SES implantation in the human coronary artery.
Sections du résumé
BACKGROUND
BACKGROUND
Although 1-month dual antiplatelet therapy (DAPT) in patients treated with bare metal stents (BMS) is well established, the optimal duration of DAPT after implantation of a drug-eluting stent (DES) is still a matter of debate. The safety of shortened DAPT is under investigation due to concern about the risk of stent thrombosis. Data on platelet activation and prothrombotic response in vivo following bioresorbable polymer sirolimus-eluting stent (BP-SES) implantation are scarce.
OBJECTIVES
OBJECTIVE
The aim of our study was to compare the early thrombogenicity of BP-SES with that of BMS in an aortic rat model.
METHODS AND RESULTS
RESULTS
Overall, 30 rats underwent stent implantation in the abdominal aorta: BMS (Pro-Kinetic Energy; N=15) and BP-SES (Ultimaster Tansei; N=15) were compared in terms of their early thrombogenicity. CD62P exposure at the platelet surface and fibrinogen binding at the integrin receptor were not different between BMS and BP-SES over time. The thrombus coverage of the scaffold (0 vs. 0.1%, P=0.84) was similarly low in both groups at Day 28; thrombotic deposits had totally disappeared at Day 84. The endothelial strut coverage was similarly high at 1 month (90 vs. 95%, P=0.64) and 3 months (87 vs. 97%, P=0.99) following BMS and BP-SES implantation, respectively.
CONCLUSIONS
CONCLUSIONS
This study demonstrates the low early thrombogenicity of a BP-SES implanted in an aortic rat model, which did not differ from a BMS. These data could be helpful to support the safety of a shortened 1-month DAPT duration following BP-SES implantation in the human coronary artery.
Types de publication
Journal Article
Langues
eng
Pagination
72-83Informations de copyright
AJCD Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Cardiol J. 2016;23(6):657-666
pubmed: 27976797
PLoS One. 2019 Jan 10;14(1):e0209841
pubmed: 30629613
EuroIntervention. 2016 Jun 12;12(2):e167-74
pubmed: 27290676
Atherosclerosis. 2013 Aug;229(2):462-8
pubmed: 23880206
EuroIntervention. 2016 Oct 20;12(9):1164-1173
pubmed: 27753601
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
Cardiovasc Diagn Ther. 2015 Aug;5(4):254-63
pubmed: 26331109
Am Heart J. 2019 Aug;214:134-141
pubmed: 31203158
Thromb Haemost. 2012 Jun;107(6):1161-71
pubmed: 22535188
Am J Cardiol. 1999 Apr 1;83(7):1006-11
pubmed: 10190510
Eur Heart J. 2012 Dec;33(24):3078-87
pubmed: 23091199
EuroIntervention. 2019 Mar 20;14(16):1685-1693
pubmed: 29619983
JACC Cardiovasc Interv. 2015 Aug 17;8(9):1248-1260
pubmed: 26292590
JAMA. 2019 Jun 25;321(24):2414-2427
pubmed: 31237644
EuroIntervention. 2019 Jan 20;14(13):1420-1427
pubmed: 29741484
J Am Coll Cardiol. 1998 Jan;31(1):224-30
pubmed: 9426044
EuroIntervention. 2009 Jan;4(4):502-8
pubmed: 19284073
Circ Cardiovasc Interv. 2015 Feb;8(2):e001441
pubmed: 25634905
J Am Coll Cardiol. 2015 Sep 1;66(9):1036-45
pubmed: 26314532
Cardiovasc Interv Ther. 2018 Jan;33(1):55-61
pubmed: 27822890
Am Heart J. 2019 Mar;209:97-105
pubmed: 30703644
Circ Cardiovasc Interv. 2017 Dec;10(12):
pubmed: 29246909